Rogers, E <br/><br/>
Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the Multicentre All Ireland Immunotherapy Study Group.  [electronic resource] 

 -  European urology  Mar 2000 
 - 261-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0302-2838 
<br/><br/><label>Standard No.: </label>10.1159/000052353  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Carcinoma, Renal Cell--drug therapy<br/>Feasibility Studies<br/>Female<br/>Humans<br/>Injections, Subcutaneous<br/>Interferon Type I--administration & dosage<br/>Interleukin-2--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Recombinant Proteins--administration & dosage<br/>Risk Factors<br/>Survival Rate